期刊
RHEUMATOLOGY
卷 52, 期 1, 页码 5-14出版社
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kes189
关键词
rheumatic disease; RA; malignancy; mortality; comorbidity; cancer; treatment SLE; SS; myositis; risk factors
类别
资金
- Abbott
- Pfizer
- Roche
- Amgen
- Biogen Idec
- Centocor
- Cypress
- Eli Lily Inc.
- Genentech
- Hoffmann-LaRoche
- Human Genome Sciences
- Janssen Biotech Inc
- Novartis
- Schering
- UCB Group
- Aspreva
- Aventis
- Bristol-Myers-Squibb
Patients with systemic autoimmune rheumatic diseases, particularly RA, SLE, SS and idiopathic inflammatory myopathies, are at increased risk of developing malignancies. Cancer occurrence adds to the disease burden in these patients, adversely affecting quality of life and life expectancy. This risk is related to the pathobiology of the underlying rheumatic disease including the inflammatory burden, immunological defects, and personal and environmental exposure such as smoking and some viral infections. Immunomodulatory therapies, especially chemotherapeutic agents, are also associated with an increased risk of cancer in these conditions. The decision to use immunomodulating therapies in patients with rheumatic disease must take into account the disease severity, expectations for disease control, comorbidities and host and environmental risk factors for cancer. Effective screening and monitoring strategies are important in reducing the risk of cancer in these patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据